-
Mylan completes acquisition of Agila from Strides Arcolab
PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.
Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.
-
Pharmacy Compounding Accreditation Board seeks new executive director
WASHINGTON — The Pharmacy Compounding Accreditation Board is looking for a new executive director following the departure of Joe Cabaleiro, the group said Wednesday.
The formal search will start in January, and the new executive director will oversee accreditation programs for compounding pharmacies and lead compounding initiatives to enhance patient care and improve quality practices. Interested parties may contact National Community Pharmacists Association chief of staff Beverly Martin.